{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '35', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'post last', 'administration unless', 'DC', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Participants will be', 'contacted by telephone', 'on C1D8 to assess for', 'development of early', 'Phone contact', 'X', 'toxicity. If early toxicity', 'is suspected, an', 'unscheduled visit can', 'occur before C1D15 if', 'deemed necessary by the', 'investigator.', 'Height', 'X', 'Vital signs, weight', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital signs must be taken', 'in the clinic.', 'ECG at screening, C1D1,', 'C2D1, D1 of every', 'fourth cycle (12 weeks)', 'thereafter (eg, C6, C10,', '12-lead ECG with', 'X', 'X', 'X', 'X', 'C14, etc.) up until', 'QTc measurement', 'discontinuation. ECGs', 'are only required at the', 'EOT Visit for those', 'participants that had', 'received lenvatinib.', 'Additional assessments', 'ECHO/MUGA', 'X', 'X', 'may be performed as', 'clinically indicated.', 'At screening, perform', 'ECOG performance', 'within 7 days before C1', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'status', 'but before', 'randomization.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '36', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', '1', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Report AEs occurring', 'within 30 days after the', 'last dose of study', 'intervention.', 'Report SAEs occurring', 'within 90 days after the', 'AE monitoring', 'X', 'X', 'last dose of study', 'intervention, or 30 days', 'after the last dose of', 'study intervention if a', 'new anticancer therapy is', 'initiated, whichever is', 'earlier.', 'All screening', 'procedures should be', 'performed within', 'Laboratory Procedures/Assessments Analysis by Local Laboratory', '28 days of', 'randomization, unless', 'otherwise noted.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}